Pınar BALCI, Nesrin AKTÜRK, Ali İbrahim SEVİNÇ, İlknur Bilkay GÖRKEN, Zeliha GÜZELÖZ, Merih GÜRAY DURAK, Zümre ARICAN ALICIKUŞ

Treatment results in patients with ductal carcinoma in situ treated with adjuvant radiotherapy

Background/aim: The aim of this study was to evaluate the treatment results of patients undergoing adjuvant radiotherapy (ART) afterbreast surgery with the diagnosis of ductal carcinoma in situ (DCIS).Materials and methods: A total of 61 women who had undergone radiotherapy following extensive surgical excision were enrolled. Allpatients underwent 50 Gy ART. Survival analysis was performed using Kaplan–Meier analysis and SPSS 20.0.Results: The median age was 52 years (range: 28–86). The median follow-up period after RT was 92 months (range: 23–237). Themedian overall survival and distant and regional recurrence-free and disease-specific survival was 96 months (range: 26–240), whiledisease-free and local recurrence-free survival was 96 months (range: 22–240). While the 15-year and 20-year overall survival rates were87% and 87%, respectively, the recurrence-free survival rates were 98% and 98%, respectively; the rates of disease-specific survival were100% and 100%, respectively.Conclusion: The results of this study with a long follow-up period have shown that ART in DCIS is an effective treatment method toprovide local disease control. However, further large studies are needed to identify the prognostic factors.

PDF

___

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A et al. American Cancer Society. Cancer statistics, 2004. CA Cancer Journal for Clinicians 2004; 54 (1): 8-29.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics 2015. CA Cancer Journal for Clinicians 2015; 65 (1): 5-29. doi: 10.3322/caac.21254.
3. Trentham-Dietz A, Newcomb PA, Storer BE, Remington PL. Risk factors for carcinoma in situ of the breast. Cancer Epidemiology Biomarkers and Prevention 2000; 9: 697-703.
4. Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Human Pathology 1992; 23 (10): 1095-1097.
5. Badve S, A’Hern RP, Ward AM, Millis RR, Pinder SE et al. Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: a comparative study with long follow-up. Human Pathology 1998; 29 (9): 915-923.
6. Millis RR, Thynne GSJ. In situ intraduct carcinoma of the breast: a long-term follow-up study. British Journal of Surgery 1975; 62: 957-962.
7. Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of longterm follow-up. Cancer 2005; 103: 2481-2484. doi: 10.1002/ cncr.21069
8. O’Sullivan MJ, Morrow M. Ductal carcinoma in situ—current management. Surgical Clinics of North America 2007; 87 (2): 333-351. doi: 10.1016/j.suc.2007.01.006
9. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New England Journal of Medicine 2002; 347 (16): 1233-1241. doi: 10.1056/ NEJMoa022152
10. Van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ et al. Long-term results of a randomized trial comparing breastconserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. Journal of National Cancer Institute 2000; 92 (14): 1143-1150. doi: 10.1093/ jnci/92.14.1143
11. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R et al. Twenty-year follow-up of a randomized study comparing breastconserving surgery with radical mastectomy for early breast cancer. New England Journal of Medicine 2002; 347 (16): 1227- 1232. doi: 10.1056/NEJMoa020989
12. Goodwin A, Parker S, Ghersi D, Wilcken N. Post-operative radiotherapy for ductal carcinoma in situ of the breast—a systematic review of the randomised trials. Breast 2009; 18 (3): 143-149. doi: 10.1016/j.breast.2009.04.003
13. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Seminars in Oncology 2001; 28 (4): 400-418.
14. EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group; Bijker N, Meijnen P, Peterse JL et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-A study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Journal of Clinical Oncology 2006; 24 (21): 3381-3387. doi: 10.1200/JCO.2006.06.1366
15. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS et al. UK Coordinating Committee on Cancer Research; Ductal Carcinoma in situ Working Party; DCIS trialists in the UK, Australia, and New Zealand. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: Randomised controlled trial. Lancet 2003; 362 (9378): 95-102.
16. Holmberg L, Garmo H, Granstrand B, Ringberg A, Arnesson LG et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. Journal of Clinical Oncology 2008; 26 (8): 1247-1252.
17. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. New England Journal of Medicine 2004; 350: 1430-1441. doi: 10.1056/NEJMra031301
18. Silverstein MJ. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. American Journal of Surgery 2003; 186 (4): 337-343.
19. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). International Journal of Radiation Oncology, Biology, Physics 1995; 31 (5): 1341-1346. doi: 10.1016/0360-3016(95)00060-C
20. Harris JR, Levene MB, Svensson G, Hellman S. Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. International Journal of Radiation Oncology, Biology, Physics 1979; 5: 257-261.
21. Brinton LA, Sherman ME, Carreon JD, Anderson WF. Recent trends in breast cancer among younger women in the United States. Journal of National Cancer Institute 2008; 100 (22): 1643-1648. doi: 10.1093/jnci/djn344
22. Hwang ES. The impact of surgery on ductal carcinoma in situ outcomes: the use of mastectomy. Journal of National Cancer Institute Monographs 2010; 2010 (41): 197-199. doi: 10.1093/ jncimonographs/lgq032
23. Fisher ER, Leeming R, Anderson S, Redmond C, Fisher B. Conservative management of intraductal carcinoma (DCIS) of the breast. Journal of Surgical Oncology 1991; 47: 139-147.
24. Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ et al. Long-term outcome of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP-17 and B-24 randomized clinical trials for DCIS. Journal of National Cancer Institute 2011; 103: 478-488. doi: 10.1093/jnci/djr027
25. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, BallardBarbash R. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Archives of Internal Medicine 2000; 160 (7): 953-958.
26. Motwani SB, Goyal S, Moran MS, Chhabra A, Haffty BG. Ductal carcinoma in situ treated with breast-conserving surgery and radiotherapy: a comparison with ECOG study 5194. Cancer 2011; 117 (6): 1156-1162. doi: 10.1002/cncr.25623
27. Manders JB, Kuerer HM, Smith BD, McCluskey C, Farrar WB et al. Clinical utility of the 12-Gene DCIS Score Assay: impact on radiotherapy recommendations for patients with ductal carcinoma in situ. Annals of Surgical Oncology 2017; 24 (3): 660-668. doi: 10.1245/s10434-016-5583-7
28. Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. Journal of Clinical Oncology 2007; 25 (22): 3259-3265. doi: 10.1200/JCO.2007.11.4991
29. Romestaing P, Lehingue Y, Carrie C, Coquard R, Montbarbon X et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. Journal of Clinical Oncology 1997; 15 (3): 963- 968. doi: 10.1200/JCO.1997.15.3.963
30. Moran MS, Zhao Y, Ma S, Kirova Y, Fourquet A et al. Association of radiotherapy boost for ductal carcinoma in situ with local control after whole-breast radiotherapy. JAMA Oncology 2017; 3 (8): 1060-1068. doi: 10.1001/jamaoncol.2016.6948
31. Wong P, Lambert C, Agnihotram RV, David M, Duclos M et al. Ductal carcinoma in situ—the influence of the radiotherapy boost on local control. International Journal of Radiation Oncology, Biology, Physics 2012; 82 (2): e153-e158. doi: 10.1016/j.ijrobp.2011.03.045
32. Shapiro-Wright HM, Julian TBJ. Sentinel lymph node biopsy and management of the axilla in ductal carcinoma in situ. National Cancer Institute Monographs 2010; 2010 (41): 145- 149. doi: 10.1093/jncimonographs/lgq026
33. Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP et al. National Surgical Adjuvant Breast and Bowel Project. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. Journal of Clinical Oncology 2002; 20 (20): 4141-4149. doi: 10.1200/JCO.2002.11.101
34. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER et al. Tamoxifen in treatment of intraductal breast cancer. National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353 (9169): 1993- 2000. doi: 10.1016/S0140-6736(99)05036-9
35. START Trialists’ Group; Bentzen SM, Agrawal RK, Aird EG, Barrett JM et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology 2008; 9 (4): 331-341. doi: 10.1016/S1470- 2045(08)70077-9
36. START Trialists’ Group; Bentzen SM, Agrawal RK, Aird EG, Barrett JM et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008; 371 (9618): 1098-1107. doi: 10.1016/S0140- 6736(08)60348-7
37. Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R et al. Long-term results of hypofractionated radiation therapy for breast cancer. New England Journal of Medicine 2010; 362 (6): 513-520. doi: 10.1056/NEJMoa0906260.
38. Lalani N, Paszat L, Sutradhar R, Thiruchelvam D, NofechMozes S et al. Long-term outcomes of hypofractionation versus conventional radiation therapy after breast-conserving surgery for ductal carcinoma in situ of the breast. International Journal of Radiation Oncology, Biology, Physics 2014; 90 (5): 1017- 1024. doi: 10.1016/j.ijrobp.2014.07.026
39. Wai ES, Lesperance ML, Alexander CS, Truong PT, Culp M et al. Effect of radiotherapy boost and hypofractionation on outcomes in ductal carcinoma in situ. Cancer 2011; 117 (1): 54-62. doi: 10.1002/cncr.25344.40
40. Williamson D, Dinniwell R, Fung S, Pintilie M, Done SJ et al. Local control with conventional and hypofractionated adjuvant radiotherapy after breast-conserving surgery for ductal carcinoma in-situ. Radiotherapy and Oncology: Journal of European Society for Therapeutic Radiology and Oncology 2010; 95 (3): 317-320. doi: 10.1016/j.radonc.2010.03.021